bs-17689R **[Primary Antibody]**

MMS22L/C6orf167 Rabbit pAb

www.bioss.com.cn
sales@bioss.com.cn
techsupport@bioss.com.cn
400-901-9800

DATASHEET

Host: Rabbit **Isotype:** IgG

Clonality: Polyclonal

GeneID: 253714 **SWISS:** Q6ZRQ5

Target: MMS22L/C6orf167

Immunogen: KLH conjugated synthetic peptide derived from human MMS22L/C6orf167: 451-550/1243.

Purification: affinity purified by Protein A

Concentration: 1mg/ml

Storage: 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Background: Making up nearly 6% of the human genome, chromosome 6 contains around 1,200 genes within 170 million base pairs of sequence. Deletion of a portion of the q arm of chromosome 6 is associated with early onset intestinal cancer suggesting the presence of a cancer susceptibility locus. Porphyria cutanea tarda is associated with chromosome 6 through the HFE gene which, when mutated, predisposes an individual to developing this porphyria. Notably, the PARK2 gene, which is associated with Parkinson's disease, and the genes encoding the major histocompatiblity complex proteins, which are key molecular components of the immune system and determine predisposition to rheumatic diseases, are also located on chromosome 6. Stickler syndrome, 21-hydroxylase deficiency and maple syrup urine disease are also associated with genes on chromosome 6. A bipolar disorder susceptibility locus has been identified on the q arm of chromosome 6. The C6orf167 gene product has been provisionally designated C6orf167 pending further characterization.

Applications: **IHC-P** (1:100-500)
IHC-F (1:100-500)
IF (1:100-500)
ICC/IF (1:100-500)
ELISA (1:5000-10000)

Reactivity: (predicted: Human, Mouse, Rat, Rabbit, Pig, Sheep, Cow)

Predicted MW.: 142 kDa

Subcellular Location: Nucleus

SELECTED CITATIONS

- **[IF=6.244]** Qiyu Luo. et al. MMS22L Expression as a Predictive Biomarker for the Efficacy of Neoadjuvant Chemoradiotherapy in Oesophageal Squamous Cell Carcinoma. Front Oncol. 2021; 11: 711642 IHC ;Human. 34660277